Amita Patnaik

8PUBLICATIONS
75CO-AUTHORS
Predictive and prognostic markersMolecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Mar 05, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.

Michael S Gordon, Richard D Carvajal, Alexander Spira

|Sep 05, 2024
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.

Sarina Piha-Paul, Shane A Olwill, Erika Hamilton

|Apr 18, 2024
Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.

Dana Piovesan, Amber E de Groot, Soonweng Cho

|Mar 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.

David S Hong, Michael Postow, Bartosz Chmielowski

|Mar 29, 2022
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Amita Patnaik, Shirish Gadgeel, Kyriakos P Papadopoulos

Pageof 2

Frequent Collaborators

2 joint publications

Sarina Piha-Paul

2 joint publications

Anthony Tolcher

1 joint publications

David S Hong

1 joint publications

Michael Postow